![Terry Pearson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Terry Pearson
Direttore Tecnico/Scientifico/R&S presso Siscapa Assay Technologies, Inc.
Posizioni attive di Terry Pearson
Società | Posizione | Inizio | Fine |
---|---|---|---|
Science Council of British Columbia | Direttore/Membro del Consiglio | 01/09/2010 | - |
CAVA Healthcare, Inc.
![]() CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Direttore/Membro del Consiglio | - | - |
Siscapa Assay Technologies, Inc.
![]() Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Direttore Tecnico/Scientifico/R&S | - | - |
Eyam Vaccines & Immunotherapeutics Ltd. | Direttore/Membro del Consiglio | 10/01/2022 | - |
Storia della carriera di Terry Pearson
Precedenti posizioni note di Terry Pearson
Società | Posizione | Inizio | Fine |
---|---|---|---|
BIOASIS TECHNOLOGIES INC. | Direttore/Membro del Consiglio | 27/03/2008 | 21/09/2017 |
Independent Dir/Board Member | 27/03/2008 | 21/09/2017 | |
MARKER THERAPEUTICS, INC. | Direttore/Membro del Consiglio | - | 05/12/2005 |
University of British Columbia | Corporate Officer/Principal | - | - |
NEVIS BRANDS INC. | Direttore/Membro del Consiglio | 16/12/2014 | - |
Independent Dir/Board Member | 16/12/2014 | - | |
University of Victoria | Corporate Officer/Principal | 01/01/1979 | - |
░░░ ░░░░░ ░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formazione di Terry Pearson
University of British Columbia | Doctorate Degree |
Statistiche
Distribuzione geografica
Canada | 7 |
Stati Uniti | 5 |
Posizioni
Director/Board Member | 7 |
Independent Dir/Board Member | 2 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Consumer Non-Durables | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
MARKER THERAPEUTICS, INC. | Health Technology |
BIOASIS TECHNOLOGIES INC. | Health Technology |
NEVIS BRANDS INC. | Health Technology |
Aziende private | 5 |
---|---|
The Terry Fox Foundation | |
Science Council of British Columbia | |
CAVA Healthcare, Inc.
![]() CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Consumer Non-Durables |
Siscapa Assay Technologies, Inc.
![]() Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Health Technology |
Eyam Vaccines & Immunotherapeutics Ltd. |
- Borsa valori
- Insiders
- Terry Pearson
- Esperienza